Nureca vs Abbott Laboratories: Fair Value & Quality
Both stocks run through our valuation models. Here is how Nureca (NURECA) and Abbott Laboratories (ABT) compare, as of Aug 18, 2026.
As of Aug 18, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Nureca trades at ₹340 versus a fair value of ₹101 (-70%), while Abbott Laboratories trades at $110 versus $74.79 (-32%).
Nureca
NURECA.NSE · INR · Health Care
-70%
upside to fair value
overvalued
Price₹340
Fair Value₹101
Quality66/100
Abbott Laboratories
ABT · USD · Health Care
-32%
upside to fair value
overvalued
Price$110
Fair Value$74.79
Quality67/100
Get comparisons like this free by email every month: the most undervalued quality stocks.
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
NurecaAbbott Laboratories
Valuation
110.4×P/E (TTM)27.7×
1.59×P/S (TTM)3.89×
1.29×P/B3.36×
22.6×EV/EBITDA15.1×
—PEG1.47×
2.1%Dividend yield2.7%
Profitability
1%Net margin14%
6%Operating margin13%
1%Return on equity12%
2%Return on assets6%
Growth
12%Revenue growth (YoY)8%
9.7%Avg. growth/yr (3Y)0.5%
-7.2%Avg. growth/yr (5Y)5.1%
Balance & size
0.00×Debt / equity0.19×
$25MMarket cap$175B
weakGrowth qualityhealthy
Abbott Laboratories leads: 5 to 8 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Nurecaof which business quality 64 · market factors 70Abbott Laboratoriesof which business quality 66 · market factors 54
ProfitabilityMargins and returns on capital today
29
50
Quality GrowthAre margins and returns improving?
80
47
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
95
65
Low VolatilityCalm price path (market factor)
54
83
MomentumPrice trend over the last 3–12 months (market factor)
68
45
52W MomentumDistance to the 52-week high (market factor)
91
37
Net IssuanceBuybacks instead of dilution
92
84
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Nureca
DCF Models₹152
Earnings-Based₹79.65
Dividend Discount₹85.36
Multiples₹89.88
Asset-Based₹127
Growth DCF₹131
Economic Profit₹102
Growth Earnings₹101
25 of 25 models see the stock below the current price.
Abbott Laboratories
DCF Models$73.01
Earnings-Based$29.42
Dividend Discount$39.73
Multiples$70.72
Asset-Based$20.05
Growth DCF$67.02
Economic Profit$37.49
Growth Earnings$70.25
26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Nureca
Bear ₹70.96Fair Value ₹101Bull ₹101
₹340 = current price (white tick)
Abbott Laboratories
Bear $51.13Fair Value $74.79Bull $94.43
$110 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Nureca · Health Care
Quality score66 · Top 25%
Fair value upside-70% · bottom 25%
Abbott Laboratories · Health Care
Quality score67 · Top 25%
Fair value upside-32% · below median
Bottom line
As of Aug 18, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Nureca trades at ₹340 versus a fair value of ₹101 (-70%), while Abbott Laboratories trades at $110 versus $74.79 (-32%).
Abbott Laboratories has the higher quality score (67/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
